In a research report released this morning, Needham analyst Alan Carr reiterated a Hold rating on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), ahead of the company’s …
In a research report sent to investors today, Needham analyst Alan Carr reiterated a Buy rating on Gilead Sciences (NASDAQ:GILD) with a price target …
In a research report published Thursday, Needham analyst Alan Carr downgraded shares of Vertex Pharmaceuticals (NASDAQ:VRTX) from Buy to Hold, following the company’s fourth-quarter financial results, which were …
Needham’s healthcare analyst Alan Carr weighed in this morning with a few insights on Gilead Sciences (NASDAQ:GILD), as the company is scheduled to report its …
In a research report sent to investors today, Needham analyst Alan Carr reiterated a Hold rating on KaloBios Pharmaceuticals (NASDAQ:KBIO), as the company yesterday …
Needham analyst Alan Carr weighed in today on shares of Cempra (NASDAQ:CEMP) maintaining a Buy rating and raising the price target to $42 (from $28), as the company announced positive …
In a research report issued today, Needham analyst Alan Carr maintained a Hold rating on Cubist Pharmaceuticals (NASDAQ:CBST), following last Friday’s news that the …
In a research report sent to investors today, Needham analyst Alan Carr maintained a Buy rating on Cempra (NASDAQ:CEMP) and raised his price target …
In a research report published this morning, Needham analyst Alan Carr maintained a Buy rating on Acadia (NASDAQ:ACAD) and raised his price target …
In a research report released today, Needham analyst Alan Carr reiterated a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a price target of …
